Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation

Read also

Amgen shares positive late-stage results for Uplizna in generalised myasthenia gravis

Amgen has shared positive top-line results from a late-stage trial of its B cell-depleting therapy Uplizna (inebilizumab-cdon) in adults with generalised myasthenia gravis (gMG).

Gepotidacin NDA Under Priority Review by FDA for Uncomplicated UTI

The FDA has accepted the New Drug Application (NDA) for investigational, first-in-class oral antibiotic gepotidacin, according to a press release from manufacturer GSK. The drug, which has a n...

GRI

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers ...

Eli Lilly will ‘build new way of doing science’ in UK amid £297m pledge to government

An Eli Lilly executive has said the company will “build a new way of doing science” as part of its £279m ($363m) pledge to boost the UK’s life science sector.  A memorandum of...